Evidence map›Paper›PMID 39463507›Full record

ArticleCureus2024

Tacrolimus-Associated Maculopathy in a Patient Following Kidney Transplantation.

Sultan Almdallaleh, Abdulhadi Altalhi, Kheira Azzaz, Oudeh Oudeh, Mohammed Radwan

Abstract readCase Reports
In one paragraph

Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sultan AlmdallalehNephrology, King Saud Medical City, Riyadh, SAU.
Abdulhadi AltalhiPediatric Nephrology, King Saud Medical City, Riyadh, SAU.
Kheira AzzazNephrology, King Saud Medical City, Riyadh, SAU.
Oudeh OudehNephrology, King Saud Medical City, Riyadh, SAU.
Mohammed RadwanOphthalmology, Cairo University, Cairo, EGY.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tacrolimus is one of the mainstay medications for renal transplantation patients. Vision loss is a rare but serious adverse effect associated with tacrolimus use. Herein, we report a male patient who developed acute vision loss during hospitalization for slow kidney graft function post-renal transplantation and 19 days after starting tacrolimus. The vision loss was associated with a recent rise in tacrolimus levels that required dose adjustment. The workup excluded cortical blindness and showed evidence of a newly developed bilateral central white cloudy inner retinal opacification resembling a cherry red spot on fundus examination. Tacrolimus toxicity was suspected, and the medication was replaced with cyclosporin. Follow-up was remarkable for mild improvement in the patient's vision and disappearance of structural changes on fundoscopy in both eyes. These findings are in keeping with a diagnosis of ischemic maculopathy. This is the first case of bilateral severe early-onset tacrolimus-associated ischemic maculopathy. According to our workup, this disease can be explained by a vasoocclusive accident at the arteriolar and venular level of the ciliomacular vascular system.

Indexed as

immunosuppressive therapiesischemic maculopathykidney transplantationsudden vision losstacrolimus

Identifiers

PMID39463507
PMCPMC11506439

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.